Cutter & CO Brokerage Inc. Acquires New Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cutter & CO Brokerage Inc. acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 768 shares of the medical research company's stock, valued at approximately $382,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bleakley Financial Group LLC raised its stake in shares of Thermo Fisher Scientific by 21.9% in the 1st quarter. Bleakley Financial Group LLC now owns 14,465 shares of the medical research company's stock valued at $7,198,000 after acquiring an additional 2,597 shares during the period. Eos Management L.P. purchased a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $4,719,000. Prudent Man Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 2.2% in the 1st quarter. Prudent Man Advisors LLC now owns 1,460 shares of the medical research company's stock valued at $726,000 after acquiring an additional 32 shares during the period. Wilkinson Global Asset Management LLC raised its stake in shares of Thermo Fisher Scientific by 0.4% in the 1st quarter. Wilkinson Global Asset Management LLC now owns 63,985 shares of the medical research company's stock valued at $31,839,000 after acquiring an additional 256 shares during the period. Finally, Marks Group Wealth Management Inc raised its stake in shares of Thermo Fisher Scientific by 3.3% in the 1st quarter. Marks Group Wealth Management Inc now owns 9,387 shares of the medical research company's stock valued at $4,671,000 after acquiring an additional 296 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research note on Tuesday, June 24th. Royal Bank Of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Finally, UBS Group lowered shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $500.00 to $460.00 in a research note on Tuesday, July 8th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $600.30.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Up 2.2%

TMO stock traded up $8.97 during midday trading on Thursday, reaching $425.28. 2,494,559 shares of the company were exchanged, compared to its average volume of 2,017,984. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The stock's 50-day simple moving average is $410.13 and its 200 day simple moving average is $473.73. The company has a market cap of $160.54 billion, a price-to-earnings ratio of 24.94, a price-to-earnings-growth ratio of 2.21 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter last year, the company earned $5.11 earnings per share. The firm's revenue for the quarter was up .2% on a year-over-year basis. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific's payout ratio is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.